SuperworthOdyssey Therapeutics ODTX
Biotechnology, Healthcare
$19.60
+2.73%
- Market cap
- $941.9M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| $1.9M | $959K | $0 | $0 | |
| R&D | $38.8M | $30.2M | $32.3M | $36.2M |
| SG&A | $8M | $13.2M | $7.3M | $10.5M |
| −$39.2M | −$41.9M | −$39.8M | −$55.5M | |
| Interest expense | $2K | $2K | $10K | $20K |
| Pre-tax income | −$38.3M | −$41.2M | −$38.2M | −$52.8M |
| $140K | $30K | $63K | −$8K | |
| Net income | −$38.4M | −$41.2M | −$38.3M | −$52.8M |
| −$39.37 | −$29.54 | −$6.77 | −$1.74 | |
| 976.1K | 1.4M | 5.7M | 30.3M |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Odyssey Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ODTXOdyssey Therapeutics | $941.9M | n/m | n/a | n/m | n/m | n/m | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | 20.9× | +23% | 54.8% | |
| Peer median | $2.2B | 15.3× | 34.2× | 4.7× | +23% | 23.5% |
More on Odyssey Therapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .